PoliticalRepoPoliticalRepo

United States · Bill · HR

H.R. 679 (94th)

Drug Safety Consumer Information and Medical Records Act

referredUnited States· United States Congress· EN

Introduced

14 January 1975

Last action

Status

Referred to House Committee on Interstate and Foreign Commerce.

Sponsors

Subjects

Discovery layer

Source updated

2 September 2025

Summary

Drug Safety, Consumer Information, and Medical Records Act - Title I: National Center for Clinical Pharmacology - Establishes, under the Public Health Service Act and within the Department of Health, Education, and Welfare, the National Center for Clinical Pharmacology to provide support, in the nature of grants, for the study of clinical pharmacology. Enumerates the nature and general provisions of such grants. Provides for the collection of data regarding drug experiences and adverse drug reactions. Calls for a study to be conducted on the inappropriate prescribing of drugs and on whether controls are needed for such inappropriate prescribing. Requires all organizations receiving assistance under this Act to review the prescribing and administering of all drugs in the course of delivery of health care. Calls for the establishment of procedures to insure the confidentiality of medical records pertaining to the experiences of a specific individual in taking drugs. Provides for Congressional inspection of medical data. Authorizes appropriations through fiscal year 1976 to carry out the purposes and projects of this title. Title II: Promotional Practices - Prohibits, under the Federal Food, Drug, and Cosmetic Act, the giving by any person engaged in the manufacture, propagation, processing, or distribution of any drug of any gift or other free promotional item having a retail value of more than $5.00 to any practitioner, pharmacist, student, or any other person engaged in the delivery of health care. Prohibits the transfer of samples and free drugs to practioners unless each such practioner has filed a written request for such drug. Places additional restrictions on the transfer of any sample or other free drug. Places a prohibition on prescription surveys. Provides for: (1) price information in drug advertising; (2) restrictions on, remainder labeling and advertising and false and misleading advertising; and (3) certification of training programs for manufactures' representatives. Title III: Drug Quality - Provides, under the Federal Food, Drug, and Cosmetic Act, for the establishment of regulations governing the requirements for proof of therapeutic equivalence of drugs. Defines the terms used in this Act. Provides procedures for certification of batches of specified kinds of drugs (other than insulin and antibiotics). Sets forth recordkeeping and reporting requirements for drugs by persons subject to registration under this Act, specifing the procedures under which any such reports shall be made available to the committees of Congress. Title IV: National Drug Compendium - Calls for the preparation of a drug compendium, listing by established name, drugs lawfully available in the United States, to provide adequate and reliable prescribing information. Sets forth the method for compilation and publication of such compendium, including, (1) the appointment of a committee to advise the Secretary on compendium matters, and (2) the requirements governing advertising of information contained in the compendium. Title V: Consumer Drug Information - Requires specified prescription drug information be included on all drug labels in such terms so that it is likely to be understood by the ordinary individual. Directs the establishment of a uniform system of coding of drugs consiting of representing: (1) the identity of the manufacturer, the drug, and the final packager; (2) the dosage form and strength of the drug; (3) the number of drug units in the immediate container. Requires that pharmacies post prescription drug prices. Directs the Secretary of Health, Education, and Welfare to identify methods for informing consumers of the costs associated with the manufacture and distribution of retail drugs. Empowers the Secretary to make grants to consumer groups for informing the public with price comparison data of drugs. Authorizes $1,000,000 to be appropriated for such grants for fiscal year 1975. Title VI: Recall Authority; Increased Criminal Penalty - Vests the Secretary with authority to recall an article of food, drug, device or cosmetic which is liable to be proceeded against on libel of information and condemnation. Increases from $1,000 to $5,000 the criminal penalty for violations of the Federal Food, Drug and Cosmetic Act.

This text is taken from the official record. PoliticalRepo does not editorialize.

Timeline

No timeline events have been ingested for this record yet.

Votes

No vote records are attached yet.

Versions

No version snapshots stored. Document URLs remain at the source.

Documents

1 official file

Sponsors

No sponsors or actors listed by the source.

Related records

No cross-record relationships stored yet.

Sources

PoliticalRepo is an index and interpretation layer, not the authoritative legal source.